Trial · NCT01905371
Amphetamine-Enhanced Stroke Recovery
NCT01905371, Phase 2, Completed, Duke University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Amphetamine-Enhanced Stroke Recovery. Trials, record NCT01905371. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01905371
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Amphetamine-Enhanced Stroke Recovery
- NCT number
- NCT01905371
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 99 participants, actual
- Lead sponsor
- Duke University
- Conditions
- Stroke
- Interventions
- Dextroamphetamine, Physical Therapy, Placebo
- First posted
- 2013-07-23
- Last updated
- 2013-07-23
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Mean Change in Fugl-Meyer Score from Baseline to 90 days Poststroke | 90 days, Baseline | The Fugl-Meyer score was determined at baseline, immediately after treatment, and 90 days poststroke in order to assess voluntary movement in both the upper and lower limbs using an ordinal scale. The mean change from baseline will be calculated at each timepoint for each study arm. |
| Secondary | Mean Change in Ambulation Speed Score from Baseline to 90 Days Poststroke | 90 days, Baseline | Ambulation speed was measured at baseline, immediately after treatment, and 90 days poststroke to indirectly measure gait quality. Walking speed was measured by using a standardized 10 meter walk test. The mean change from baseline will be calculated at each timepoint for each study arm. |
| Secondary | Mean Change in Ambulation Endurance Score from Baseline to 90 days Poststroke | 90 days, Baseline | Ambulation endurance was determined at baseline, immediately after treatment, and 90 days poststroke to indirectly measure gait quality. The poorer the gait quality the more effortful it is and the more easily patients fatigue. Ambulation endurance was assessed using the standardized 6 minute walk test. The mean change from baseline will be calculated at each timepoint for each study arm. |
| Secondary | Mean Change in the Action Research Arm Test (ARAT) score from Baseline to 90 days Poststroke | 90 days, Baseline | The ARAT score was determined at baseline, immediately after treatment, and 90 days poststroke assess arm and hand function. It tests the ability to develop gross grasp and release of cubes and spheres of defined size and weight. Pincer grasp and opposition of thumb to 3rd and 4th fingers are tested by asking the patient to pick up a marble and a 0.24 inch diameter steel ball bearing. Functional wrist pronation-supination is tested by asking the patient to pour water from a standardized cup. More difficult finger prehension wrist rotation tasks involve picking up and placing metal cylinders over wooden pegs of matching size, and placing a washer over a metal bolt. The mean change from baseline will be calculated at each timepoint for each study arm. |
| Secondary | Mean Change in the Mobility Subscale of the Functional Independence Measure from Baseline | 90 days, Baseline | The mobility subscale score was measured at baseline, immediately after treatment, and 90 days poststroke to assess the patient's ability to transfer to and from bed, chair, toilet, and tub. It also scores the patient's ability to walk and climb stairs. The mobility subscale score is computed from the more movement dependent portions of the FIM were assessed. The mean change from baseline will be calculated at each timepoint for each study arm. |
| Secondary | Mean Change in the NIH Stroke Scale Score from Baseline | 90 days, Baseline | The NIH stroke scale score was measured at baseline, immediately after treatment, and at 90 days poststroke to provide a measure of stroke impairment. Analysis of change scores for the various domains of the NIH Stroke Scale permitted the detection of possible carry-over effects. The mean change from baseline will be calculated at each timepoint for each study arm. |
| Secondary | Mean Change in Rankin Scale Score from Baseline | 90 days, Baseline | The Rankin Scale was determined at baseline, immediately after treatment, and 90 days poststroke to assess stroke-related handicap. The mean change from baseline will be calculated at each timepoint for each study arm. |
| Secondary | Mean Change in Mini-Mental State Examination Score | 90 days, Baseline | The Mini-Mental State examination score was determined at baseline, immediately after treatment, and 90 days poststroke to provide a more detailed assessment of stroke-related cognitive impairments. The mean change from baseline will be calculated at each timepoint for each study arm. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 30167675 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01905371
GET https://conductscience.org/api/trials/v1/NCT01905371/registered